July 3: The Week in Cancer News
Uterine cancer diagnoses expected to climb in the next 25 years, and some disposable e-cigarettes emit more carcinogens than traditional cigarettes.
Progress Against Cancer
Uterine cancer diagnoses expected to climb in the next 25 years, and some disposable e-cigarettes emit more carcinogens than traditional cigarettes.
The FDA has approved sunvozertinib for certain patients with EGFR-mutated non-small Cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sunvozertinib (Zegfrovy) for the treatment of adult patients...
The FDA has approved linvoseltamab-gcpt for certain patients with heavily pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with...
Incidence-based mortality is also projected to increase with disproportionately higher rates for Black women compared with white women. Incidence and mortality rates for most cancer types have been on the decline in the United...
Participating in a structured exercise program after treatment was associated with a reduced risk of recurrence in people who had colon cancer.
A single-cell atlas helped clarify diverse forms of acute myeloid leukemia, with potential implications for improving diagnostic, prognostic, and therapeutic capabilities.
Low-dose aspirin reduces cancer risk for people with Lynch syndrome, and breast cancer survivors may have lower risk for Alzheimer’s than the general public.
For June 2025, the editors of AACR's journals highlighted studies on pancreatic cancer interception, breast cancer risk prediction, and more.
Cancer Today's 2025 summer issue covers the expanded use of neoadjuvant immunotherapy, PSMA-targeted therapy for prostate cancer, and more.
A study suggests that modifying a patient’s gut microbiome could make their cancer more likely to respond to CAR T-cell therapy.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More